

Zabrina L Brumme

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6298892/publications.pdf>

Version: 2024-02-01

188
papers

9,221
citations

47006

47
h-index

48315

88
g-index

207
all docs

207
docs citations

207
times ranked

8887
citing authors

#	ARTICLE	IF	CITATIONS
1	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. <i>Journal of Infectious Diseases</i> , 2023, 227, 838-849.	4.0	31
2	Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 979-988.	3.0	7
3	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1129-1140.	4.0	65
4	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28.	6.0	64
5	HAMdetector: a Bayesian regression model that integrates information to detect HLA-associated mutations. <i>Bioinformatics</i> , 2022, 38, 2428-2436.	4.1	1
6	Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. <i>Journal of Infectious Diseases</i> , 2022, 226, 983-994.	4.0	26
7	Increased CD4 ⁺ CD8 ratio normalization with implementation of current ART management guidelines. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 729-737.	3.0	8
8	Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naïve individuals with HIV-1 subtype A1 and D infections in Uganda. <i>Aids</i> , 2021, 35, 1083-1089.	2.2	7
9	Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency. <i>Biochemical Pharmacology</i> , 2021, 186, 114462.	4.4	14
10	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	9
11	Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, British Columbia, Canada. <i>Emerging Infectious Diseases</i> , 2021, 27, 1673-1676.	4.3	38
12	Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART. <i>Frontiers in Microbiology</i> , 2021, 12, 719153.	3.5	8
13	SARS-CoV-2 RNA Quantification Using Droplet Digital RT-PCR. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 907-919.	2.8	17
14	Concordance of HIV transmission risk factors elucidated using viral diversification rate and phylogenetic clustering. <i>Evolution, Medicine and Public Health</i> , 2021, 9, 338-348.	2.5	5
15	HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). <i>Nature Communications</i> , 2021, 12, 165.	12.8	60
16	2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1818-1823.	2.8	10
17	HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy. <i>MBio</i> , 2021, 12, e0249021.	4.1	14
18	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. <i>BMJ Open</i> , 2021, 11, e054208.	1.9	7

#	ARTICLE	IF	CITATIONS
19	The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal. <i>Journal of Biological Chemistry</i> , 2020, 295, 14084-14099.	3.4	6
20	Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5. <i>PLoS Pathogens</i> , 2020, 16, e1008813.	4.7	20
21	Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4 ⁺ T Cell Subsets during Long-Term Combination Antiretroviral Therapy. <i>Journal of Virology</i> , 2020, 94, .	3.4	21
22	Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes. <i>Journal of Virology</i> , 2020, 94, .	3.4	6
23	HIV-1 variants are archived throughout infection and persist in the reservoir. <i>PLoS Pathogens</i> , 2020, 16, e1008378.	4.7	37
24	The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada. <i>Current HIV/AIDS Reports</i> , 2020, 17, 77-87.	3.1	16
25	Suboptimal Biological Sampling as a Probable Cause of False-Negative COVID-19 Diagnostic Test Results. <i>Journal of Infectious Diseases</i> , 2020, 222, 899-902.	4.0	75
26	Longitudinal within-host evolution of HIV Nef-mediated CD4, HLA and SERINC5 downregulation activity: a case study. <i>Retrovirology</i> , 2020, 17, 3.	2.0	10
27	Evaluation of Nasopharyngeal Swab Collection Techniques for Nucleic Acid Recovery and Participant Experience: Recommendations for COVID-19 Diagnostics. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa488.	0.9	21
28	T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics. <i>PLoS Pathogens</i> , 2020, 16, e1009177.	4.7	4
29	The HIV-1 latent reservoir is largely sensitive to circulating T cells. <i>ELife</i> , 2020, 9, .	6.0	25
30	Title is missing!. , 2020, 16, e1009177.		0
31	Title is missing!. , 2020, 16, e1009177.		0
32	Title is missing!. , 2020, 16, e1009177.		0
33	Title is missing!. , 2020, 16, e1009177.		0
34	Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity. <i>Cell Reports</i> , 2019, 29, 1449-1457.e5.	6.4	18
35	Detection of HIV transmission hotspots in British Columbia, Canada: A novel framework for the prioritization and allocation of treatment and prevention resources. <i>EBioMedicine</i> , 2019, 48, 405-413.	6.1	8
36	Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study. <i>Pathogens</i> , 2019, 8, 161.	2.8	4

#	ARTICLE	IF	CITATIONS
37	Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia. <i>Viruses</i> , 2019, 11, 877.	3.3	9
38	HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy. <i>Journal of Virology</i> , 2019, 93, .	3.4	35
39	Immune Correlates of Disease Progression in Linked HIV-1 Infection. <i>Frontiers in Immunology</i> , 2019, 10, 1062.	4.8	14
40	Nef-mediated inhibition of NFAT following TCR stimulation differs between HIV-1 subtypes. <i>Virology</i> , 2019, 531, 192-202.	2.4	8
41	Modulation of TCR-dependent NFAT signaling is impaired in HIV-1 Nef isolates from elite controllers. <i>Virology</i> , 2019, 530, 39-50.	2.4	6
42	Clinical and evolutionary consequences of HIV adaptation to HLA. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 194-204.	3.8	6
43	Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth. <i>Aids</i> , 2019, 33, 211-218.	2.2	18
44	HIV Subtype and Nef-Mediated Immune Evasion Function Correlate with Viral Reservoir Size in Early-Treated Individuals. <i>Journal of Virology</i> , 2019, 93, .	3.4	32
45	Genotypic and Mechanistic Characterization of Subtype-Specific HIV Adaptation to Host Cellular Immunity. <i>Journal of Virology</i> , 2019, 93, .	3.4	17
46	Inhibition of NF- κ B-dependent HIV-1 replication by the marine natural product bengamide A. <i>Antiviral Research</i> , 2018, 152, 94-103.	4.1	19
47	Novel HLA class I associations with HIV-1 control in a unique genetically admixed population. <i>Scientific Reports</i> , 2018, 8, 6111.	3.3	32
48	Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2018, 92, .	3.4	12
49	The Croton megalobotrys MÃ¼ll Arg. traditional medicine in HIV/AIDS management: Documentation of patient use, in vitro activation of latent HIV-1 provirus, and isolation of active phorbol esters. <i>Journal of Ethnopharmacology</i> , 2018, 211, 267-277.	4.1	12
50	Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico. <i>Journal of Virology</i> , 2018, 92, .	3.4	5
51	Extensive host immune adaptation in a concentrated North American HIV epidemic. <i>Aids</i> , 2018, 32, 1927-1938.	2.2	16
52	HLA-C downregulation by HIV-1 adapts to host HLA genotype. <i>PLoS Pathogens</i> , 2018, 14, e1007257.	4.7	30
53	Phylogenetic approach to recover integration dates of latent HIV sequences within-host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8958-E8967.	7.1	50
54	High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia. <i>Viruses</i> , 2018, 10, 60.	3.3	11

#	ARTICLE	IF	CITATIONS
55	Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products. <i>Viruses</i> , 2018, 10, 348.	3.3	28
56	Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection. <i>Journal of Virology</i> , 2018, 92, .	3.4	12
57	HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. <i>Journal of Clinical Investigation</i> , 2018, 128, 4074-4085.	8.2	67
58	Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. <i>Journal of Clinical Investigation</i> , 2018, 128, 1903-1912.	8.2	52
59	HIV-1 Mutational Escape from Host Immunity. , 2018, , 863-878.		0
60	Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression. <i>Journal of Virology</i> , 2017, 91, .	3.4	34
61	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. <i>Oncolmmunology</i> , 2017, 6, e1321184.	4.6	23
62	Mother-to-Child HIV Transmission Bottleneck Selects for Consensus Virus with Lower Gag-Protease-Driven Replication Capacity. <i>Journal of Virology</i> , 2017, 91, .	3.4	13
63	In vitro functional assessment of natural HIV-1 group M Vpu sequences using a universal priming approach. <i>Journal of Virological Methods</i> , 2017, 240, 32-41.	2.1	6
64	Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. <i>Aids</i> , 2017, 31, 1935-1943.	2.2	7
65	Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada. <i>PLoS ONE</i> , 2017, 12, e0184848.	2.5	5
66	A strong association of human leukocyte antigen-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection. <i>Aids</i> , 2016, 30, 681-689.	2.2	18
67	Impact of pre-adapted HIV transmission. <i>Nature Medicine</i> , 2016, 22, 606-613.	30.7	87
68	HIV-1 Vpu Mediates HLA-C Downregulation. <i>Cell Host and Microbe</i> , 2016, 19, 686-695.	11.0	127
69	Transmitted/Founder HIV-1 Subtype C Viruses Show Distinctive Signature Patterns in Vif, Vpr, and Vpu That Are Under Subsequent Immune Pressure During Early Infection. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1031-1045.	1.1	5
70	Novel Acylguanidine-Based Inhibitor of HIV-1. <i>Journal of Virology</i> , 2016, 90, 9495-9508.	3.4	17
71	Croton megalobotrys and Vitex doniana (Sweet): Traditional medicinal plants in a three-step treatment regimen that inhibit in vitro replication of HIV-1. <i>Journal of Ethnopharmacology</i> , 2016, 191, 331-340.	4.1	16
72	Relative Resistance of HLA-B to Downregulation by Naturally Occurring HIV-1 Nef Sequences. <i>MBio</i> , 2016, 7, e01516-15.	4.1	23

#	ARTICLE	IF	CITATIONS
73	Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. <i>Journal of Virology</i> , 2016, 90, 1244-1258.	3.4	13
74	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2226-2236.	7.0	26
75	Rapid HIV-1 Disease Progression in Individuals Infected with a Virus Adapted to Its Host Population. <i>PLoS ONE</i> , 2016, 11, e0150397.	2.5	13
76	Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. <i>PLoS Pathogens</i> , 2016, 12, e1005619.	4.7	97
77	Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR5 Δ 32/ Δ 32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction. <i>Scientific Reports</i> , 2015, 5, 17607.	3.3	15
78	Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naïve Japanese individuals. <i>Retrovirology</i> , 2015, 12, 98.	2.0	4
79	Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. <i>Frontiers in Immunology</i> , 2015, 6, 506.	4.8	23
80	Modest Attenuation of HIV-1 Vpu Alleles Derived from Elite Controller Plasma. <i>PLoS ONE</i> , 2015, 10, e0120434.	2.5	13
81	Screening of the Pan-African Natural Product Library Identifies Ixoratannin A-2 and Boldine as Novel HIV-1 Inhibitors. <i>PLoS ONE</i> , 2015, 10, e0121099.	2.5	38
82	Anti-APOBEC3G Activity of HIV-1 Vif Protein Is Attenuated in Elite Controllers. <i>Journal of Virology</i> , 2015, 89, 4992-5001.	3.4	20
83	Immune Screening Identifies Novel T Cell Targets Encoded by Antisense Reading Frames of HIV-1. <i>Journal of Virology</i> , 2015, 89, 4015-4019.	3.4	24
84	HIV-1 adaptation to HLA: a window into virus-host immune interactions. <i>Trends in Microbiology</i> , 2015, 23, 212-224.	7.7	85
85	Dynamic range of Nef-mediated evasion of HLA class II-restricted immune responses in early HIV-1 infection. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 248-254.	2.1	7
86	Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors. <i>Journal of Virology</i> , 2015, 89, 9639-9652.	3.4	26
87	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.	8.4	188
88	Consequences of HLA-B*13-Associated Escape Mutations on HIV-1 Replication and Nef Function. <i>Journal of Virology</i> , 2015, 89, 11557-11571.	3.4	19
89	A robust and scalable TCR-based reporter cell assay to measure HIV-1 Nef-mediated T cell immune evasion. <i>Journal of Immunological Methods</i> , 2015, 426, 104-113.	1.4	22
90	Global Database-Driven Assessment of HIV-1 Adaptation to the Immune Repertoires of Human Populations. <i>Journal of Virology</i> , 2015, 89, 10693-10695.	3.4	5

#	ARTICLE	IF	CITATIONS
91	Mutational Immune Escape in HIV-1 Infection. , 2015, , 667-706.		1
92	GWATCH: a web platform for automated gene association discovery analysis. GigaScience, 2014, 3, 18.	6.4	5
93	Genotypic and Functional Impact of HIV-1 Adaptation to Its Host Population during the North American Epidemic. PLoS Genetics, 2014, 10, e1004295.	3.5	45
94	Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5393-400.	7.1	85
95	An Evaluation of Phylogenetic Methods for Reconstructing Transmitted HIV Variants using Longitudinal Clonal HIV Sequence Data. Journal of Virology, 2014, 88, 6181-6194.	3.4	11
96	Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology, 2014, 11, 64.	2.0	15
97	Using Viral Dynamics to Connect Clinical Markers of Disease Progression to Sequence Evolution during HIV Infection. AIDS Research and Human Retroviruses, 2014, 30, A223-A224.	1.1	1
98	Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population. Journal of Virology, 2014, 88, 4764-4775.	3.4	47
99	Transmitted Escape Mutations Lead to Accelerated HIV-1 Disease Progression and Largely Define the Relative Contribution of HLA Alleles to Control. AIDS Research and Human Retroviruses, 2014, 30, A40-A40.	1.1	0
100	Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: Association with disease progression and influence of immune pressure. Virology, 2014, 468-470, 214-225.	2.4	20
101	Switching and emergence of CTL epitopes in HIV-1 infection. Retrovirology, 2014, 11, 38.	2.0	13
102	Impaired Nef Function Is Associated with Early Control of HIV-1 Viremia. Journal of Virology, 2014, 88, 10200-10213.	3.4	33
103	HIV-1 Mutational Escape from Host Immunity. , 2014, , 1-19.		1
104	Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology, 2013, 10, 1.	2.0	102
105	Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology, 2013, 10, 100.	2.0	68
106	Naturally-arising amino acid polymorphisms of HIV-1 Nef that differentially modulate downregulation of HLA-A and HLA-B molecules. Retrovirology, 2013, 10, .	2.0	0
107	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	12.6	352
108	Significant Reductions in Gag-Protease-Mediated HIV-1 Replication Capacity during the Course of the Epidemic in Japan. Journal of Virology, 2013, 87, 1465-1476.	3.4	14

#	ARTICLE	IF	CITATIONS
109	Dynamic range of Nef functions in chronic HIV-1 infection. <i>Virology</i> , 2013, 439, 74-80.	2.4	30
110	A method for Killer-cell Immunoglobulin-like Receptor (KIR) 3DL1/3DS1 genotyping using DNA recovered from frozen plasma. <i>Journal of Immunological Methods</i> , 2013, 391, 154-162.	1.4	0
111	Frequent and Variable Cytotoxic-T-Lymphocyte Escape-Associated Fitness Costs in the Human Immunodeficiency Virus Type 1 Subtype B Gag Proteins. <i>Journal of Virology</i> , 2013, 87, 3952-3965.	3.4	43
112	Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection. <i>Scientific Reports</i> , 2013, 3, 3097.	3.3	35
113	Operationalizing the One Health approach: the global governance challenges. <i>Health Policy and Planning</i> , 2013, 28, 778-785.	2.7	113
114	Distinct HIV-1 Escape Patterns Selected by Cytotoxic T Cells with Identical Epitope Specificity. <i>Journal of Virology</i> , 2013, 87, 2253-2263.	3.4	30
115	No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial. <i>PLoS ONE</i> , 2013, 8, e71758.	2.5	11
116	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. <i>ELife</i> , 2013, 2, e01123.	6.0	126
117	Lack of Association between HLA Class II Alleles and <i>In Vitro</i> Replication Capacities of Recombinant Viruses Encoding HIV-1 Subtype C Gag-Protease from Chronically Infected Individuals. <i>Journal of Virology</i> , 2012, 86, 1273-1276.	3.4	8
118	Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection. <i>PLoS Pathogens</i> , 2012, 8, e1002529.	4.7	306
119	Intersubtype Differences in the Effect of a Rare p24 Gag Mutation on HIV-1 Replicative Fitness. <i>Journal of Virology</i> , 2012, 86, 13423-13433.	3.4	9
120	Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1. <i>Journal of Virology</i> , 2012, 86, 13202-13216.	3.4	99
121	Widespread Impact of HLA Restriction on Immune Control and Escape Pathways of HIV-1. <i>Journal of Virology</i> , 2012, 86, 5230-5243.	3.4	114
122	Aminopeptidase Substrate Preference Affects HIV Epitope Presentation and Predicts Immune Escape Patterns in HIV-Infected Individuals. <i>Journal of Immunology</i> , 2012, 188, 5924-5934.	0.8	30
123	Uncommon Pathways of Immune Escape Attenuate HIV-1 Integrase Replication Capacity. <i>Journal of Virology</i> , 2012, 86, 6913-6923.	3.4	33
124	Impact of HLA-B*81-Associated Mutations in HIV-1 Gag on Viral Replication Capacity. <i>Journal of Virology</i> , 2012, 86, 3193-3199.	3.4	57
125	Increasingly Successful Highly Active Antiretroviral Therapy Delays the Emergence of New HLA Class I-Associated Escape Mutations in HIV-1. <i>Clinical Infectious Diseases</i> , 2012, 54, 1652-1659.	5.8	11
126	Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure. <i>Current Opinion in Virology</i> , 2012, 2, 599-605.	5.4	8

#	ARTICLE	IF	CITATIONS
127	Minor contribution of HLA class I-associated selective pressure to the variability of HIV-1 accessory protein Vpu. <i>Biochemical and Biophysical Research Communications</i> , 2012, 421, 291-295.	2.1	9
128	TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. <i>Nature Immunology</i> , 2012, 13, 691-700.	14.5	203
129	Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial. <i>PLoS ONE</i> , 2012, 7, e34134.	2.5	5
130	HLA class I sequence-based typing using DNA recovered from frozen plasma. <i>Journal of Immunological Methods</i> , 2012, 382, 40-47.	1.4	36
131	Reduced Replication Capacity of NL4-3 Recombinant Viruses Encoding Reverse Transcriptase-Integrase Sequences From HIV-1 Elite Controllers. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 100-108.	2.1	59
132	Epithelial adhesion molecules can inhibit HIV-1-specific CD8+ T-cell functions. <i>Blood</i> , 2011, 117, 5112-5122.	1.4	31
133	Definition of the viral targets of protective HIV-1-specific T cell responses. <i>Journal of Translational Medicine</i> , 2011, 9, 208.	4.4	143
134	Immune-mediated attenuation of HIV-1. <i>Future Virology</i> , 2011, 6, 917-928.	1.8	14
135	Influence of Gag-Protease-Mediated Replication Capacity on Disease Progression in Individuals Recently Infected with HIV-1 Subtype C. <i>Journal of Virology</i> , 2011, 85, 3996-4006.	3.4	50
136	In Vitro Selection of Clinically Relevant Bevirimat Resistance Mutations Revealed by "Deep" Sequencing of Serially Passaged, Quasispecies-Containing Recombinant HIV-1. <i>Journal of Clinical Microbiology</i> , 2011, 49, 201-208.	3.9	16
137	Factors Associated With Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2011, 203, 976-983.	4.0	29
138	Progression to AIDS in South Africa Is Associated with both Reverting and Compensatory Viral Mutations. <i>PLoS ONE</i> , 2011, 6, e19018.	2.5	57
139	Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. <i>Journal of Experimental Medicine</i> , 2010, 207, 61-75.	8.5	52
140	Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers. <i>Journal of Virology</i> , 2010, 84, 7581-7591.	3.4	118
141	Gag-Protease-Mediated Replication Capacity in HIV-1 Subtype C Chronic Infection: Associations with HLA Type and Clinical Parameters. <i>Journal of Virology</i> , 2010, 84, 10820-10831.	3.4	87
142	HLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers. <i>Journal of Virology</i> , 2010, 84, 1212-1212.	3.4	1
143	Early Selection in Gag by Protective HLA Alleles Contributes to Reduced HIV-1 Replication Capacity That May Be Largely Compensated for in Chronic Infection. <i>Journal of Virology</i> , 2010, 84, 11937-11949.	3.4	111
144	Efficacious Early Antiviral Activity of HIV Gag- and Pol-Specific HLA-B*2705-Restricted CD8 + T Cells. <i>Journal of Virology</i> , 2010, 84, 10543-10557.	3.4	84

#	ARTICLE	IF	CITATIONS
145	Phylogenetic Analysis of Population-Based and Deep Sequencing Data to Identify Coevolving Sites in the nef Gene of HIV-1. <i>Molecular Biology and Evolution</i> , 2010, 27, 819-832.	8.9	59
146	HLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers. <i>Journal of Virology</i> , 2009, 83, 3407-3412.	3.4	67
147	Transmission and Long-Term Stability of Compensated CD8 Escape Mutations. <i>Journal of Virology</i> , 2009, 83, 3993-3997.	3.4	58
148	HLA-Associated Alterations in Replication Capacity of Chimeric NL4-3 Viruses Carrying gag-protease from Elite Controllers of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2009, 83, 140-149.	3.4	112
149	Impact of Select Immunologic and Virologic Biomarkers on CD4 Cell Count Decrease in Patients with Chronic HIV-1 Subtype C Infection: Results from Sinikithemba Cohort, Durban, South Africa. <i>Clinical Infectious Diseases</i> , 2009, 49, 956-964.	5.8	19
150	HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphocyte Recognition. <i>Journal of Virology</i> , 2009, 83, 2743-2755.	3.4	261
151	Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification. <i>Journal of Experimental Medicine</i> , 2009, 206, 1215-1218.	8.5	15
152	Adaptation of HIV-1 to human leukocyte antigen class I. <i>Nature</i> , 2009, 458, 641-645.	27.8	408
153	Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. <i>Retrovirology</i> , 2009, 6, 72.	2.0	33
154	HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins. <i>PLoS ONE</i> , 2009, 4, e6687.	2.5	148
155	HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective. <i>Microbes and Infection</i> , 2008, 10, 455-461.	1.9	44
156	Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection. <i>Journal of Virology</i> , 2008, 82, 9216-9227.	3.4	162
157	CD4-Dependent Characteristics of Coreceptor Use and HIV Type 1 V3 Sequence in a Large Population of Therapy-Naïve Individuals. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 219-228.	1.1	23
158	Phylogenetic Dependency Networks: Inferring Patterns of CTL Escape and Codon Covariation in HIV-1 Gag. <i>PLoS Computational Biology</i> , 2008, 4, e1000225.	3.2	116
159	Statistical Resolution of Ambiguous HLA Typing Data. <i>PLoS Computational Biology</i> , 2008, 4, e1000016.	3.2	50
160	Genetic Characterization of Human Immunodeficiency Virus Type 1 in Elite Controllers: Lack of Gross Genetic Defects or Common Amino Acid Changes. <i>Journal of Virology</i> , 2008, 82, 8422-8430.	3.4	114
161	Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection. <i>Aids</i> , 2008, 22, 1277-1286.	2.2	67
162	Antigen Load and Viral Sequence Diversification Determine the Functional Profile of HIV-1-Specific CD8+ T Cells. <i>PLoS Medicine</i> , 2008, 5, e100.	8.4	205

#	ARTICLE	IF	CITATIONS
163	Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1. PLoS Pathogens, 2007, 3, e94.	4.7	153
164	A 21-Base Pair Insertion/Duplication at Codon 69 of the HIV Type 1 Reverse Transcriptase in a Patient Undergoing Multiple Nucleoside Therapy. AIDS Research and Human Retroviruses, 2007, 23, 895-899.	1.1	3
165	Reply to Waters et al.. Clinical Infectious Diseases, 2007, 45, 1244-1245.	5.8	0
166	A Simple Screening Approach to Reduce B*5701-Associated Abacavir Hypersensitivity on the Basis of Sequence Variation in HIV Reverse Transcriptase. Clinical Infectious Diseases, 2007, 44, 1503-1508.	5.8	35
167	Effects of Human Leukocyte Antigen Class I Genetic Parameters on Clinical Outcomes and Survival after Initiation of Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2007, 195, 1694-1704.	4.0	31
168	HIV therapy, hepatitis C virus infection, antibiotics and obesity, a mitochondria killer mix?. Aids, 2006, 20, 1343-1345.	2.2	2
169	Short Communication: HIV VprR77Q Mutation Does Not Influence Clinical Response of Individuals Initiating Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2006, 22, 615-618.	1.1	13
170	The impact of human genetic variation on HIV disease in the era of HAART. AIDS Reviews, 2006, 8, 78-87.	1.0	13
171	Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. Aids, 2005, 19, 549-554.	2.2	35
172	Molecular and Clinical Epidemiology of CXCR4-Using HIV-1 in a Large Population of Antiretroviral-Naïve Individuals. Journal of Infectious Diseases, 2005, 192, 466-474.	4.0	260
173	Predictors of HIV Drug-Resistance Mutations in a Large Antiretroviral-Naïve Cohort Initiating Triple Antiretroviral Therapy. Journal of Infectious Diseases, 2005, 191, 339-347.	4.0	386
174	Short communication. Association of the CCR5Δ32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen. Antiviral Therapy, 2005, 10, 849-53.	1.0	5
175	Association of the CCR5Δ32 Mutation with Clinical Response and >5-year Survival following Initiation of First Triple Antiretroviral Regimen. Antiviral Therapy, 2005, 10, 849-853.	1.0	7
176	Antiretroviral Resistance among HIV-Infected Persons Who Have Died in British Columbia, in the Era of Modern Antiretroviral Therapy. Journal of Infectious Diseases, 2004, 190, 285-292.	4.0	36
177	Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. Aids, 2004, 18, F1-F9.	2.2	80
178	Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury. Critical Care, 2003, 7, R176.	5.8	44
179	Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. Aids, 2003, 17, 201-208.	2.2	85
180	Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naïve individuals initiating antiretroviral therapy. Antiviral Therapy, 2003, 8, 91-6.	1.0	8

#	ARTICLE	IF	CITATIONS
181	Prevalence and clinical implications of insertions in the HIV-1 p6 ^{Gag} N-terminal region in drug-naïve individuals initiating antiretroviral therapy. <i>Antiviral Therapy</i> , 2003, 8, 91-96.	1.0	16
182	Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy. <i>Antiviral Therapy</i> , 2003, 8, 395-402.	1.0	4
183	A Mutation in the 3' Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance. <i>Journal of Virology</i> , 2002, 76, 6836-6840.	3.4	42
184	No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy. <i>Aids</i> , 2002, 16, 1929-1933.	2.2	37
185	Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients. <i>New England Journal of Medicine</i> , 2002, 346, 811-820.	27.0	591
186	CCR5 ^{Δ32} and promoter polymorphisms are not correlated with initial virological or immunological treatment response. <i>Aids</i> , 2001, 15, 2259-2266.	2.2	29
187	Human Immunodeficiency Virus Type 1 Protease Cleavage Site Mutations Associated with Protease Inhibitor Cross-Resistance Selected by Indinavir, Ritonavir, and/or Saquinavir. <i>Journal of Virology</i> , 2001, 75, 589-594.	3.4	121
188	Attenuated HIV-1 Nef But Not Vpu Function in a Cohort of Rwandan Long-Term Survivors. <i>Frontiers in Virology</i> , 0, 2, .	1.4	0